Using the PEG framework with analyst consensus forward EPS growth of 23.6%, Boston Scientific Corporation has a fair value of $82.02 based on NTM EPS (FY2026) of $3.47. The current PEG ratio is 0.86.
PEG < 1 = bargain, 1–1.5 = fair, > 2 = expensive.
PEG is most informative for high-growth companies — the PEG sweet spot.
| EPS Growth RateForward | 23.6% |
| Adjusted Growth (clamped 8–25%) | 23.6% |
| Fair P/E | 23.6x |
| NTM EPS (FY2026) | $3.47 |
| Fair Value | $82.02 |
| Period | EPS Est. | Growth | Analysts |
|---|---|---|---|
| FY2025 (actual) | $1.94 | — | — |
| FY2026E | $3.47 | +78.8% | 25 |
| FY2027E | $3.92 | +13.0% | 24 |
| FY2028E | $4.44 | +13.3% | 19 |
| FY2029E | $4.98 | +12.1% | 10 |
| FY2030E | $5.61 | +12.6% | 16 |
5Y Forward EPS CAGR: 23.6%
| Year | Net Income | EPS | YoY |
|---|---|---|---|
| FY2021 | $1.0B | $0.69 | — |
| FY2022 | $698.0M | $0.45 | -35.1% |
| FY2023 | $1.6B | $1.07 | +140.6% |
| FY2024 | $1.9B | $1.25 | +16.5% |
| FY2025 | $2.9B | $1.94 | +55.2% |
4Y Historical EPS CAGR: 29.6%
The PEG Fair Value uses the Price/Earnings-to-Growth framework. A stock is fairly valued when its P/E ratio equals its earnings growth rate (PEG = 1.0). This model adds dividend yield to the growth rate per the original PEGY formula.
Growth rate priority: analyst consensus forward EPS CAGR (when ≥ 3 analysts cover the stock), falling back to historical EPS CAGR. Using EPS rather than net income avoids distortion from share buybacks. The growth rate is clamped between 8% and 25% — below 8% would undervalue stable earners, while above 25% would overvalue unsustainable spikes.